Page 1259 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 68 The Polycythemias 1105

12. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation 22. Kiladjian JJ, Chevret S, Dosquet C, et al: Treatment of polycythemia
leading to constitutive signalling causes polycythaemia vera. Nature vera with hydroxyurea and pipobroman: final results of a randomized
434:1144–1148, 2005. trial initiated in 1980. J Clin Oncol 29:3907–3913, 2011.
13. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation 23. Najfeld V, Montella L, Scalise A, et al: Exploring polycythaemia vera
of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790, with fluorescence in situ hybridization: additional cryptic 9p is the
2005. most frequent abnormality detected. Br J Haematol 119:558–566,
14. Jones AV, Chase A, Silver RT, et al: JAK2 haplotype is a major risk 2002.
factor for the development of myeloproliferative neoplasms. Nat Genet 24. Arber DA, Orazi A, Hasserjian R, et al: The 2016 revision to the World
41:446–449, 2009. Health Organization classification of myeloid neoplasms and acute
15. Tapper W, Jones AV, Kralovics R, et al: Genetic variation at MECOM, leukemia. Blood 127:2391–2405, 2016.
TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neo- 25. Barosi G, Mesa R, Finazzi G, et al: Revised response criteria for poly-
plasms. Nat Commun 6:6691, 2015. cythemia vera and essential thrombocythemia: an ELN and IWG-MRT
16. Ortmann CA, Kent DG, Nangalia J, et al: Effect of mutation order on consensus project. Blood 121:4778–4781, 2013.
myeloproliferative neoplasms. N Engl J Med 372:601–612, 2015. 26. Sergueeva AI, Miasnikova GY, Polyakova LA, et al: Complications in
17. Jamieson CH, Gotlib J, Durocher JA, et al: The JAK2 V617F mutation children and adolescents with Chuvash polycythemia. Blood 125:414–
occurs in hematopoietic stem cells in polycythemia vera and predisposes 415, 2015.
toward erythroid differentiation. Proc Natl Acad Sci USA 103:6224–6229, 27. Bjorkholm M, Derolf AR, Hultcrantz M, et al: Treatment-related risk
2006. factors for transformation to acute myeloid leukemia and myelodysplastic
18. Rampal R, Ahn J, Abdel-Wahab O, et al: Genomic and functional syndromes in myeloproliferative neoplasms. J Clin Oncol 29:2410–2415,
analysis of leukemic transformation of myeloproliferative neoplasms. 2011.
Proc Natl Acad Sci USA 111:E5401–E5410, 2014. 28. Soutou B, Aractingi S: Myeloproliferative disorder therapy: assessment
19. Wang L, Swierczek SI, Drummond J, et al: Whole-exome sequencing and management of adverse events–a dermatologist’s perspective.
of polycythemia vera revealed novel driver genes and somatic mutation Hematol Oncol 27(Suppl 1):11–13, 2009.
shared by T cells and granulocytes. Leukemia 28:935–938, 2014. 29. Stein BL, Tiu RV: Biological rationale and clinical use of interferon in the
20. Landolfi R, Marchioli R, Kutti J, et al: Efficacy and safety of low-dose classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon
aspirin in polycythemia vera. N Engl J Med 350:114–124, 2004. Cytokine Res 33:145–153, 2013.
21. Marchioli R, Finazzi G, Specchia G, et al: Cardiovascular events and 30. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al: Ruxolitinib versus
intensity of treatment in polycythemia vera. N Engl J Med 368:22–33, standard therapy for the treatment of polycythemia vera. N Engl J Med
2013. 372:426–435, 2015.